Redeye: Amniotics H1 2024 - Merger with Magle
Redeye comments on Amniotics' H1 report 2024, which will likely be its last before the merger with Magle.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/